mesylate


Also found in: Medical, Encyclopedia, Wikipedia.

mes·y·late

 (mĕs′ə-lāt′)
n.
A salt, ester, or anion of methanesulfonic acid. Also called methanesulfonate.

[me(thane)s(ulfonic acid) + -yl + -ate.]
References in periodicals archive ?
* Saquinavir mesylate (Fortovase [soft gel capsule], Invirase [hard gel capsule], SQV), Hoffmann-La Roche
M2 EQUITYBITES-March 5, 2019-Breckenridge wins final US FDA approval for Imatinib Mesylate Tablets ANDA
M2 PHARMA-March 5, 2019-Breckenridge wins final US FDA approval for Imatinib Mesylate Tablets ANDA
announced today that a presentation on the updated analysis of a global Phase Ib/II clinical study (ENHANCE 1 / Study 218) of its in-house discovered and developed anticancer agent eribulin mesylate (halichondrin class microtubule dynamics inhibitor, product name: Halaven, eribulin) in combination with the anti-PD-1 therapy pembrolizumab (product name: KEYTRUDA) developed by Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada), in patients with metastatic triple-negative breast cancer was given at a spotlight session of the 40th Annual San Antonio Breast Cancer Symposium (SABCS) held from December 5 to 9, 2017.
Bromocriptine mesylate is a quick release formulation of bromocriptine.
The Food and Drag Administration has approved Eisai Inc.'s Halaven (eribulin mesylate), a type of chemotherapy, for the treatment of liposarcoma that cannot be removed by surgery or is at an advanced stage (metastatic).
and Merck, through a subsidiary, have entered a clinical trial collaboration to evaluate the safety, tolerability and efficacy of Merck's anti-PD-1 therapy, pembrolizumab (KEYTRUDA), in combination with Eisai oncology compounds lenvatinib mesylate (a multi-targeting RTK inhibitor marketed in the U.S.
Imatinib mesylate was started at a daily dose of 400 mg.
-- The majority of a Food and Drug Administration advisory panel recommended against approval of a low-dose formulation of paroxetine mesylate as a treatment for menopausal vasomotor symptoms, citing minimal benefits over placebo in clinical trials and the potential risks associated with treatment.
The FDA has advised pharmacists to dispense the anticoagulant medication dabigatran etexilate mesylate (Pradaxa) only in the original manufacturer bottles or blister packages because of concerns about product breakdown, according to a MedWatch statement.
According to results of a final-stage clinical trial into the drug eribulin mesylate, the med could extend life by 2.5 months on average in women with advanced breast cancer, reports The Scotsman.